PKIB

Across TCGA pan-cancer cohorts, PKIB mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PKIB data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PKIB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PKIB expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PKIB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.785	0.364	.006	43	view →
LSCC	DFS	Median	II,III,IV	0.842	1.000	.003	13	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PKIB–PDAC (DFS)

Open the PDAC breakdown →